242 related articles for article (PubMed ID: 26833741)
21. Establishment of patient-derived xenograft model of peritoneal mucinous carcinomatosis with signet ring cells and in vivo study on the efficacy and toxicity of intraperitoneal injection of 5-fluorouracil.
Lin YL; Zhang J; Yan FC; Jiang X; Ma R; Yang ZR; Xu HB; Peng Z; Chen Q; Li Y
Cancer Med; 2020 Feb; 9(3):1104-1114. PubMed ID: 31814323
[TBL] [Abstract][Full Text] [Related]
22. Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation.
Yan H; Pestieau SR; Shmookler BM; Sugarbaker PH
Mod Pathol; 2001 Mar; 14(3):164-71. PubMed ID: 11266521
[TBL] [Abstract][Full Text] [Related]
23. Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients.
Jackson SL; Fleming RA; Loggie BW; Geisinger KR
Mod Pathol; 2001 Jul; 14(7):664-71. PubMed ID: 11454998
[TBL] [Abstract][Full Text] [Related]
24. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
[TBL] [Abstract][Full Text] [Related]
25. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases.
Nonaka D; Kusamura S; Baratti D; Casali P; Younan R; Deraco M
Histopathology; 2006 Oct; 49(4):381-7. PubMed ID: 16978201
[TBL] [Abstract][Full Text] [Related]
26. Mucin as a therapeutic target in pseudomyxoma peritonei.
Choudry HA; O'Malley ME; Guo ZS; Zeh HJ; Bartlett DL
J Surg Oncol; 2012 Dec; 106(7):911-7. PubMed ID: 22585683
[TBL] [Abstract][Full Text] [Related]
27. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
[TBL] [Abstract][Full Text] [Related]
28. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
30. Extraperitoneal presentation of pseudomyxoma peritonei as retroperitoneal invasion with skin fistula-a case report.
Chang-Yun L; Mao-Chi H; Yonemura Y; Ishibashi H; Sako S; Kitai T; Matsuki N
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1998-2001. PubMed ID: 22202264
[TBL] [Abstract][Full Text] [Related]
31. Tumor-stroma ratio as a new prognosticator for pseudomyxoma peritonei: a comprehensive clinicopathological and immunohistochemical study.
Ma R; Lin YL; Li XB; Yan FC; Xu HB; Peng Z; Li Y
Diagn Pathol; 2021 Dec; 16(1):116. PubMed ID: 34895284
[TBL] [Abstract][Full Text] [Related]
32. Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei.
Robella M; Vaira M; Borsano A; Mossetti C; DE Simone M
Anticancer Res; 2018 Feb; 38(2):929-932. PubMed ID: 29374723
[TBL] [Abstract][Full Text] [Related]
33. Pulmonary metastases in pseudomyxoma peritonei syndrome.
Mortman KD; Sugarbaker PA; Shmookler BM; DeGuzman VC; Soberman MS
Ann Thorac Surg; 1997 Nov; 64(5):1434-6. PubMed ID: 9386716
[TBL] [Abstract][Full Text] [Related]
34. Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei.
Nummela P; Leinonen H; Järvinen P; Thiel A; Järvinen H; Lepistö A; Ristimäki A
Hum Pathol; 2016 Aug; 54():47-54. PubMed ID: 27038681
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of the presence of epithelial cell clusters in the ascites of patients with pseudomyxoma peritonei.
Ishida M; Mizumoto A; Yonemura Y; Kashu I; Takemura S; Tsuta K
Diagn Cytopathol; 2019 Oct; 47(10):1024-1027. PubMed ID: 31218847
[TBL] [Abstract][Full Text] [Related]
36. [Pseudomyxoma peritonei : a cause of ascites that should not be underestimated].
Sinatra T; Coimbra Marques C
Rev Med Liege; 2018 Jul; 73(7-8):408-412. PubMed ID: 30113783
[TBL] [Abstract][Full Text] [Related]
37. Borderline-like mucinous tumor arising in mature cystic teratoma of the ovary associated with pseudomyxoma peritonei.
Hwang JH; So KA; Modi G; Lee JK; Lee NW; Lee KW; Kim I
Int J Gynecol Pathol; 2009 Jul; 28(4):376-80. PubMed ID: 19483624
[TBL] [Abstract][Full Text] [Related]
38. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential.
Ronnett BM; Kurman RJ; Zahn CM; Shmookler BM; Jablonski KA; Kass ME; Sugarbaker PH
Hum Pathol; 1995 May; 26(5):509-24. PubMed ID: 7750935
[TBL] [Abstract][Full Text] [Related]
39. Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry.
Nummela P; Saarinen L; Thiel A; Järvinen P; Lehtonen R; Lepistö A; Järvinen H; Aaltonen LA; Hautaniemi S; Ristimäki A
Int J Cancer; 2015 Mar; 136(5):E282-9. PubMed ID: 25274248
[TBL] [Abstract][Full Text] [Related]
40. [Recurrence of pseudomyxoma peritonei with liver and splenic metastases: about a case and literature review].
Azzakhmam M; Zouaidia F; Jahid A; Znati K; Bernoussi Z; Mahassini N
Pan Afr Med J; 2018; 30():225. PubMed ID: 30574243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
